左乙拉西坦治疗2岁以下婴幼儿癫痫有效性及安全性研究

叶高波; 董建鹏; 李丹; 刘宇; 王雪莹; 杨琳; 黄绍平

doi:10.11852/zgetbjzz2017-25-10-18

PDF(678 KB)

中国儿童保健杂志 ›› 2017, Vol. 25 ›› Issue (10) : 1041-1044. DOI: 10.11852/zgetbjzz2017-25-10-18

临床研究与分析

左乙拉西坦治疗2岁以下婴幼儿癫痫有效性及安全性研究

叶高波¹,董建鹏²,李丹¹,刘宇¹,王雪莹¹,杨琳¹,黄绍平¹

作者信息 +

Study on the effectiveness and safety of Levetiracetam in the treatment of epilepsy in infants under 2 years old

YE Gao-bo¹,DONG Jian-peng²,LI Dan¹,LIU Yu¹,WANG Xue-ying¹,YANG Lin¹,HUANG Shao-ping¹

Author information +

文章历史 +

摘要

目的评估2岁以下癫痫婴幼儿应用左乙拉西坦(LEV)的疗效及安全性,为临床有效防治提供参考依据。方法对2010年1月-2011年12月西安交通大学第二附属医院儿科神经专科住院确诊的2岁以下癫痫患儿中,服用LEV的39例患儿进行临床分析,收集患儿发作类型、家族史、影像学等资料,并进行为期6~72个月的随访,评估患儿治疗情况、疗效及不良反应等。结果左乙拉西坦单药治疗终量有82.7%的患儿为中低剂量,添加治疗剂量组70%的患儿为高剂量。左乙拉西坦治疗2 岁以下癫痫患儿,6个月总有效率为82.1%,完全控制率为61.5%。其中,对于局灶性发作、强直阵挛发作有效率分别为76%和55.6%,对于失张力及肌阵挛发作效果差。单药及添加治疗的不良反应发生率均较低,提示左乙拉西坦具有较高安全性。结论左乙拉西坦是一种广谱有效的抗癫痫药物,作为单药治疗或添加治疗对部分或全面性发作均具有良好疗效,具有较高的耐受性及保留率,是2岁内儿童癫痫一种有益的选择。

Abstract

Objective To evaluate the efficacy and safety of levetiracetam used in the infants of epilepsy under 2 years old. Methods A total of 39 patients who were diagnosed with epilepsy,under the age of 2,taken the levetiracetam,hospitalized in pediatric neurological from January 2010 to December 2011 were retrospectively evaluated.Seizure type,family history and imaging were collected.Patients were followed up for 6~72 months to evaluate the treatment condition,efficacy and adverse reactions. Results The treatment dosage in monotherapy group was mainly given as a lower dosage (82.7%),while that in add-on therapy group was mainly in high doses (70%).After 6 months' follow-up,the total effective rate was 82.1%,and the total control rate was 61.5%.Among them,the efficacy rates in focal seizure and the tonic-clonic seizure were 76% and 55.6%.The levetiracetam may be useless on the atonic seizure and myoclonic seizure.Also,the adverse reactions rarely occurred,suggesting that the levetiacetam was safe. Conclusion Levetiracetam is a broad-spectrum antiepileptic drug and has high tolerance and retention rate.It is promising to be a helpful choice for the epilepsy children within 2 years old.

导出引用

叶高波,董建鹏,李丹,刘宇,王雪莹,杨琳,黄绍平. 左乙拉西坦治疗2岁以下婴幼儿癫痫有效性及安全性研究[J]. 中国儿童保健杂志. 2017, 25(10): 1041-1044 https://doi.org/10.11852/zgetbjzz2017-25-10-18

YE Gao-bo,DONG Jian-peng,LI Dan,LIU Yu,WANG Xue-ying,YANG Lin,HUANG Shao-ping. Study on the effectiveness and safety of Levetiracetam in the treatment of epilepsy in infants under 2 years old[J]. Chinese Journal of Child Health Care. 2017, 25(10): 1041-1044 https://doi.org/10.11852/zgetbjzz2017-25-10-18

中图分类号： R179

参考文献

[1] 沈晓明,王卫平.儿科学[M].北京:人民卫生出版社,2008:182-184.
[2] Kanemura H,Sano F,Tando T,et al.Efficacy and safety of add-onlevetiracetam in refractory childhood epilepsy[J].Brain and Development,2013,35(5):386-391.
[3] Robert S,Carlos A,Alexis A,et al.A practical clinical definition of epilepsy[J].Epilepsia,2014,1:1-8.
[4] Kwan P,Brodie MJ.Early identification of refractory epilepsy[J].N Engl J Med,2000,342(5):314-319.
[5] Brodie MJ,Barry SJ,Bamagous GA,et al.Patterns of treatment response in newly diagnosed epilepsy[J].Neurology,2012,78(20):1548-1554.
[6] 刘腾.左乙拉西坦的药理和临床评价[J].中国新药杂志,2007,16(9):733-735.
[7] Mohamad Z,Koubeissi MD.Monotherapy in newly diagnosed epi-lepsy:Levetiracetam versus standard anticonvulsants[J].Epilepsy Currents,2014,14(5):255-256.
[8] Pina-Garzn JE,Schiemann-Delgado J,Yang H,et al.Adjunctive levertiracetam in patients aged 1 month to <4 years with partial onset seizures:subpopulation analysis of a prospective,open label extension study of up to 48 weeks[J].Clin Ther,2010,32(11):1935-1950.
[9] Li J,Xiao N,Chen S.Efficacy and tolerability of levetiracetam in children with epilepsy[J].Brain & Development,2011,33(2):145-151.
[10] Pina-Garzn JE,Schiemann-Delgado J,Yang H,et al.Adjunctive levertiracetam in patients aged 1 month to <4 years with partial onset seizures:subpopulation analysis of a prospective,open label extension study of up to 48 weeks[J].Clin Ther,2010,32(11):1935-1950.
[11] 李立敏,王宁,胡海鹏,等.左乙拉西坦治疗儿童癫痫疗效观察[J].山东医药,2016,54(2):80-81.
[12] Lee YJ,Kang HC,Kim HD,et al.Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy[J].Pediatr Neurol,2010,42(2):86-92.
[13] güder R,Güzel O,A

In H,et al.Efficacy and safety of IV levetiracetam in children with acute repetitive seizures[J].Pediatric Neurology,2014,51(5):688-695.
[14] Gujjar AR,Nandhagopal R,Jacob PC,et al.Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures:A prospective,randomized study[J].Seizure,2017,49:8-12.
[15] Tekgül H,Gencpinar P,avuo

lu D,et al.The efficacy,tolerability and safety of levetiracetam therapy in a pediatric population[J].Seizure,2016,36:16-21.
[16] Grosso S,Franzoni E,Coppola G,et al.Efficacy and safety of levetiracetam:an add-on trial in children with refractory epilepsy[J].Seizure,2005,14(4):248-253.
[17] Xiao F,An D,Deng H,et al.Evaluation of levetiracetam and valproic acid as low-dose monotherapies for children with typical benign childhood epilepsy with centrotemporal spikes (BECTS)[J].Seizure,2014,23(9):756-761.